Ausgewählte Datenmodelle

Sie müssen eingeloggt sein, um mehrere Datenmodelle auszuwählen und diese herunterzuladen oder zu analysieren.

8 Suchergebnisse.
Relevanz Bewertung Neue zuerst Alte zuerst

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 11 - Therapieende

- 20.11.17 - 1 Formular, 7 Itemgruppen, 53 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Physical Examination, Laboratory Data, Diagnostic procedures, Results, Progress, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 11 - Therapieende (Woche 28) Toxizitäten / Unerwünschte Ereignisse / Hospitalisierungen werden im 1. Follow up dokumentiert. Das 1. Follow-up findet 3 Monate nach der letzten Chemotherapie statt.

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 10

- 20.11.17 - 1 Formular, 9 Itemgruppen, 65 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Physical Examination, Laboratory Data, Disease Progression, Additive Chemotherapy, Capecitabine, Life quality, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 10 - Chemotherapie-Zyklus 6 (Woche 25)

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 9

- 20.11.17 - 1 Formular, 7 Itemgruppen, 62 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Physical Examination, Laboratory Data, Additive Chemotherapy, Capecitabine, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 8 - Chemotherapie-Zyklus 5 (Woche 22)

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 8

- 20.11.17 - 1 Formular, 10 Itemgruppen, 71 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Adverse Event, Physical Examination, Laboratory Data, Disease Progression, Diagnostic procedures, Postoperative Chemotherapy, Capecitabine, Life quality, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 8 - Chemotherapie-Zyklus 4 (Woche 19)

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 7 - Entlassung

- 19.11.17 - 1 Formular, 8 Itemgruppen, 58 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Hospital stay information, Physical Examination, Laboratory Data, Non-surgical Complications, Surgical Complications, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 7 – Entlassung

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 4

- 16.11.17 - 1 Formular, 8 Itemgruppen, 57 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Physical Examination, Laboratory Data, Diagnostic procedures, Results, Disease Progression, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 4 – Ende Chemotherapie-Zyklus 3 (Woche 9)

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 3

- 16.11.17 - 1 Formular, 8 Itemgruppen, 64 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Physical Examination, Laboratory Data, Disease Progression, Preoperative Chemotherapy, Capecitabine, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 3 – Chemotherapie-Zyklus 3 (Woche 6)

Cytoreductive Surgery (CRS) With/Without HIPEC in Gastric Cancer With Peritoneal Carcinomatosis (GASTRIPEC) - Visit 2

- 16.11.17 - 1 Formular, 8 Itemgruppen, 64 Datenelemente, 1 Sprache
Itemgruppen: Administrative Documentation, Physical Examination, Laboratory Data, Disease Progression, Preoperative Chemotherapy, Capecitabine, Adverse Event, Administrative Documentation
Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction NCT-Identifier: NCT02158988 Source: Prof. Dr. med. Beate Rau, MBA Charité Universitätsmedizin Berlin Visit 2 – Chemotherapie-Zyklus 2 (Woche 3)

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video